EP 211: Building hope for inherited blindness and deafness with Justin Porcano of Save Sight Now

EP 211: Building hope for inherited blindness and deafness with Justin Porcano of Save Sight Now

by Sano Genetics

Life & Natural Systems Medicine & Health MJCGCongenital diseases and disordersMJCG1Hereditary diseases and disorders
🎙 Sano Genetics 👥 942 📅 October 30, 2025 ⏱ 32 min 👁 44 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

Usher syndromegene therapyAAVclinical trialspatient advocacy

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Justin Porcano, co-founder and executive director of Save Sight Now, a nonprofit dedicated to finding treatments for Usher syndrome type 1B (USH1B). Justin shares his personal journey after his daughter Leah was diagnosed with USH1B, which led him to establish the organization. He discusses the major hurdles in developing therapies, including the large size of the MYO7A gene, the lack of suitable animal models, and the absence of defined clinical endpoints. Save Sight Now has invested in developing animal models such as a porcine model and a non-human primate model, as well as natural history studies to establish endpoints. Justin explains how he used design thinking and AI to quickly learn about the disease and research landscape. The conversation covers advances in gene delivery, including dual AAV approaches and RNA editing, as well as the importance of early intervention and the potential of antioxidants to slow retinal degeneration. Justin also discusses the decision to become an independent nonprofit, the need for stronger collaboration between patient organizations and biotech companies, and the organization’s future plans, including a fundraising gala. The episode highlights the critical role of patient advocacy in accelerating rare disease research.

203 words

Critical Evaluation

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the challenges and progress in developing therapies for a rare genetic disease. Justin Porcano’s perspective as a parent and nonprofit leader offers a unique and compelling argument for the importance of patient-driven research initiatives. He clearly articulates the bottlenecks in therapeutic development, such as gene size and lack of animal models, and explains how his organization strategically addresses them. The argumentation is solid, grounded in his direct experience and interactions with researchers, though it is primarily anecdotal and lacks detailed scientific evidence. The discussion is informative and persuasive, highlighting the need for collaboration and the potential of emerging technologies.

Scientific Rigor, Source Quality, Title Accuracy

The podcast demonstrates a reasonable level of scientific rigor, with Justin referencing specific research efforts and collaborations. However, the sources cited are primarily organizational and personal, with no direct references to peer-reviewed publications. The title accurately reflects the content, focusing on building hope for inherited blindness and deafness. The discussion is well-structured and informative, but the lack of external sources limits the depth of scientific validation. The podcast does not include a public advertising segment, and the content is presented as an expert opinion based on the guest’s experience.

209 words

Title / Content Match

The title accurately reflects the content, focusing on building hope for inherited blindness and deafness through the work of Save Sight Now.

Quality & Reliability

7/10

The podcast features an expert interview with a patient advocate and nonprofit leader, providing credible insights into rare disease research and advocacy. However, it lacks peer-reviewed data and relies on anecdotal and organizational perspectives.

Chapters

Cited Sources

  • Save Sight Now — Official website of the nonprofit organization discussed in the episode.
  • Podcast review link — Link provided in the description for rating and reviewing the podcast.

Concurring Sources

Contribution & Novelties

This podcast offers a unique perspective on rare disease advocacy, highlighting the role of patient organizations in accelerating research. It provides an insider’s view of the challenges and strategies in developing therapies for Usher syndrome type 1B, including the use of novel animal models and gene delivery approaches. The discussion emphasizes the importance of collaboration between patient groups and biotech companies, a topic not commonly covered in scientific literature.

Pour aller plus loin :

120 words

Radar Profile

The radar profile shows a balanced performance across all dimensions, with slightly higher scores in information quantity and reliability, reflecting the podcast's informative and credible nature. The lower score in technical level indicates that the content is accessible to a general audience.

Reliability 7/10